Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 2, 2012, Pages 101-110

  Reddy, P Hemachandra ^a,b   Shirendeb, Ulziibat P ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Abnormal mitochondrial dynamics; BACHD mouse; Defective axonal transport; Mitochondrial trafficking; Mutant huntingtin; RNA silencing

Indexed keywords

CREATINE; CYTOCHROME C OXIDASE; CYTOCHROME OXIDASE 1; DIMEBON; DYNAMIN; DYNAMIN I; HUNTINGTIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOCHONDRIAL PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RAPAMYCIN; RESVERATROL; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR NRF2; UBIDECARENONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AUTOPHAGY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUNTINGTON CHOREA; MITOCHONDRION; NERVE CELL LESION; NERVE FIBER TRANSPORT; NEUROPROTECTION; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SYNAPSE VESICLE; SYNAPTIC MEMBRANE; UBIQUITINATION;

AXONAL TRANSPORT; HUMANS; HUNTINGTON DISEASE; MITOCHONDRIA; MUTATION; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; SYNAPSES;

EID: 84855165944     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.10.016     Document Type: Review

References (159)

1. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44:559-577.
2. Folstein S.E. Huntington's Disease 1990, Johns Hopkins University Press.
3. Montoya A., Price B.H., Menear M., Lepage M. Brain imaging and cognitive dysfunctions in Huntington's disease. J. Psychiatry Neurosci. 2006, 31:21-29.
4. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10:83-98.
5. Byers R.K., Gilles F.H., Fung C. Huntington's disease in children: neuropathologic study of four cases. Neurology 1973, 23:561-569.
6. Spargo E., Everall I.P., Lantos P.L. Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. J. Neurol. Neurosurg. Psychiatry 1993, 56:487-491.
7. Politis M., Pavese N., Tai Y.F., Tabrizi S.J., Barker R.A., Piccini P. Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain 2008, 131:2860-2869.
8. Soneson C., Fontes M., Zhou Y., Denisov V., Paulsen J.S., Kirik D., Petersén A. Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiol. Dis. 2010, 40:531-543. Huntington Study Group PREDICT-HD investigators.
9. Gray M., Shirasaki D.I., Cepeda C., André V.M., Wilburn B., Lu X.H., Tao J., Yamazaki I., Li S.H., Sun Y.E., Li X.J., Levine M.S., Yang X.W. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 2008, 28:6182-6195.
10. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
11. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
12. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
13. Reddy P.H., Williams M., Charles V., Garrett L., Pike-Buchanan L., Whetsell W.O., Miller G., Tagle D.A. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat. Genet. 1998, 20:198-202.
14. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., Slunt H.H., Ratovitski T., Cooper J.K., Jenkins N.A., Copeland N.G., Price D.L., Ross C.A., Borchelt D.R. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 1999, 8:397-407.
15. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., Jamot L., Li X.J., Stevens M.E., Rosemond E., Roder J.C., Phillips A.G., Rubin E.M., Hersch S.M., Hayden M.R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23:181-192.
16. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., Efstratiadis A., Zeitlin S., Chesselet M.F. Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knock-in mouse models of Huntington's disease. J. Neurosci. Res. 1999, 58:515-532.
17. Wheeler V.C., Auerbach W., White J.K., Srinidhi J., Auerbach A., Ryan A., Duyao M.P., Vrbanac V., Weaver M., Gusella J.F., Joyner A.L., MacDonald M.E. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 1999, 8:115-122.
18. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000, 101:57-66.
19. Reddy P.H., Mao P., Manczak M. Mitochondrial structural and functional dynamics in Huntington's disease. Brain Res. Rev. 2009, 61:33-48.
20. Kim J., Moody J.P., Edgerly C.K., Bordiuk O.L., Cormier K., Smith K., Beal M.F., Ferrante R.J. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum. Mol. Genet. 2010, 19:3919-3935.
21. Shirendeb U., Reddy A.P., Manczak M., Calkins M.J., Mao P., Tagle D.A., Reddy P.H. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum. Mol. Genet. 2011, 20:1438-1455.
22. Shirendeb U.P., Calkins M.J., Manczak M., Anekonda V., Dufour B., McBride J.L., Mao P., Reddy P.H. Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. Hum. Mol. Genet. Oct 13 2011, (Epub ahead of print).
23. Song W., Chen J., Petrilli A., Liot G., Klinglmayr E., Zhou Y., Poquiz P., Tjong J., Pouladi M.A., Hayden M.R., Masliah E., Ellisman M., Rouiller I., Schwarzenbacher R., Bossy B., Perkins G., Bossy-Wetzel E. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat. Med. 2011, 17:377-382.
24. Reddy P.H., Williams M., Tagle D.A. Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci. 1999, 22:248-255.
25. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
26. Kegel K.B., Meloni A.R., Yi Y., Kim Y.J., Doyle E., Cuiffo B.G., Sapp E., Wang Y., Qin Z.H., Chen J.D., Nevins J.R., Aronin N., DiFiglia M. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C terminal binding protein, and represses transcription. J. Biol. Chem. 2002, 277:7466-7476.
27. Kegel K.B., Sapp E., Yoder J., Cuiffo B., Sobin L., Kim Y.J., Qin Z.H., Hayden M.R., Aronin N., Scott D.L., Isenberg G., Goldmann W.H., DiFiglia M. Huntingtin associates with acidic phospholipids at the plasma membrane. J. Biol. Chem. 2005, 280:36464-36473.
28. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 2002, 5:731-736.
29. Choo Y.S., Johnson G.V., MacDonald M., Detloff P.J., Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 2004, 13:1407-1420.
30. Truant R., Atwal R., Burtnik A. Hypothesis: huntingtin may function in membrane association and vesicular trafficking. Biochem. Cell Biol. 2006, 84:912-917.
31. Strehlow A.N., Li J.Z., Myers R.M. Wild-type huntingtin participates in protein trafficking between the Golgi and the extracellular space. Hum. Mol. Genet. 2007, 16:391-409.
32. Atwal R.S., Xia J., Pinchev D., Taylor J., Epand R.M., Truant R. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum. Mol. Genet. 2007, 16:2600-2615.
33. Orr A.L., Li S., Wang C.E., Li H., Wang J., Rong J., Xu X., Mastroberardino P.G., Greenamyre J.T., Li X.J. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci. 2008, 28:2783-2792.
34. Zoghbi H.Y., Orr H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 2000, 23:217-247.
35. Wacker J.L., Zareie M.H., Fong H., Sarikaya M., Muchowski P.J. Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat. Struct. Mol. Biol. 2004, 11:1215-1222.
36. Poirier M.A., Li H., Macosko J., Cai S., Amzel M., Ross C.A. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 2002, 277:41032-41037.
37. Thakur A.K., Jayaraman M., Mishra R., Thakur M., Chellgren V.M., Byeon I.J., Anjum D.H., Kodali R., Creamer T.P., Conway J.F., Gronenborn A.M., Wetzel R. Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat. Struct. Mol. Biol. 2009, 16:380-389.
38. Legleiter J., Lotz G.P., Miller J., Ko J., Ng C., Williams G.L., Finkbeiner S., Patterson P.H., Muchowski P.J. Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment. J. Biol. Chem. 2009, 284:21647-21658.
39. Sathasivam K., Lane A., Legleiter J., Warley A., Woodman B., Finkbeiner S., Paganetti P., Muchowski P.J., Wilson S., Bates G.P. Identical oligomeric and fibrillary structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. Hum. Mol. Genet. 2010, 19:65-78.
40. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
41. Mezler M., Barghorn S., Schoemaker H., Gross G., Nimmrich V. Aβ oligomer directly modulates P/Q-type calcium currents in Xenopus oocytes. Br. J. Pharmacol. Aug 30 2011, (Epub ahead of print). 10.1111/j.1476-5381.2011.01646.x.
42. Veloso A.J., Yoshikawa H., Cheng X.R., Tamiya E., Kerman K. Optical trapping for the characterization of amyloid-beta aggregation kinetics. Analyst Aug 26 2011, (Epub ahead of print).
43. Hou L., Liu Y., Wang X., Ma H., He J., Zhang Y., Yu C., Guan W., Ma Y. The effects of amyloid-β(42) oligomer on the proliferation and activation of astrocytes in vitro. In Vitro Cell. Dev. Biol. Anim. Aug 20 2011, (Epub ahead of print).
44. Klaver A.C., Coffey M.P., Smith L.M., Bennett D.A., Finke J.M., Dang L., Loeffler D.A. ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects. J. Neuroinflammation 2011, 8:93.
45. Manczak M., Calkins M.J., Reddy P.H. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum. Mol. Genet. 2011, 20:2495-2509.
46. Bruggink K.A., Kuiperij H.B., Verbeek M.M., El-Agnaf O.M., Tokuda T. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2011, 77:510-511.
47. Kim Y.M., Jang W.H., Quezado M.M., Oh Y., Chung K.C., Junn E., Mouradian M.M. Proteasome inhibition induces α-synuclein SUMOylation and aggregate formation. J. Neurol. Sci. 2011, 307:157-161.
48. Gadad B.S., Britton G.B., Rao K.S. Targeting oligomers in neurodegenerative disorders: lessons from α-synuclein, tau, and amyloid-β peptide. J. Alzheimers Dis. 2011, 24(Suppl. 2):223-232.
49. Caruana M., Högen T., Levin J., Hillmer A., Giese A., Vassallo N. Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds. FEBS Lett. 2011, 585:1113-1120.
50. Hüls S., Högen T., Vassallo N., Danzer K.M., Hengerer B., Giese A., Herms J. AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced α-synuclein oligomers. J. Neurochem. 2011, 117:868-878.
51. Lee H.J., Baek S.M., Ho D.H., Suk J.E., Cho E.D., Lee S.J. Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers. Exp. Mol. Med. 2011, 43:216-222.
52. Giehm L., Svergun D.I., Otzen D.E., Vestergaard B. Low-resolution structure of a vesicle disrupting α-synuclein oligomer that accumulates during fibrillation. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3246-3251.
53. Behrends C., Langer C.A., Boteva R., Böttcher U.M., Stemp M.J., Schaffar G., Rao B.V., Giese A., Kretzschmar H., Siegers K., Hartl F.U. Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Mol. Cell 2006, 23:887-897.
54. Ellisdon A.M., Thomas B., Bottomley S.P. The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J. Biol. Chem. 2006, 281:16888-16896.
55. Kitamura A., Kubota H., Pack C.G., Matsumoto G., Hirayama S., Takahashi Y., Kimura H., Kinjo M., Morimoto R.I., Nagata K. Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nat. Cell Biol. 2006, 8:1163-1170.
56. Nagai Y., Inui T., Popiel H.A., Fujikake N., Hasegawa K., Urade Y., Goto Y., Naiki H., Toda T. A toxic monomeric conformer of the polyglutamine protein. Nat. Struct. Mol. Biol. 2007, 14:332-340.
57. Sánchez I., Mahlke C., Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003, 421:373-379.
58. Schaffar G., Breuer P., Boteva R., Behrends C., Tzvetkov N., Strippel N., Sakahira H., Siegers K., Hayer-Hartl M., Hartl F.U. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol. Cell 2004, 15:95-105.
59. Takahashi Y., Okamoto Y., Popiel H.A., Fujikake N., Toda T., Kinjo M., Nagai Y. Detection of polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy. J. Biol. Chem. 2007, 282:24039-24048.
60. Tanaka M., Machida Y., Nishikawa Y., Akagi T., Hashikawa T., Fujisawa T., Nukina N. Expansion of polyglutamine induces the formation of quasi-aggregate in the early stage of protein fibrillization. J. Biol. Chem. 2003, 278:34717-34724.
61. Lajoie P., Snapp E.L. Formation and toxicity of soluble polyglutamine oligomers in living cells. PLoS One 2010, 5:e15245.
62. Van Raamsdonk J.M., Metzler M., Slow E., Pearson J., Schwab C., Carroll J., Graham R.K., Leavitt B.R., Hayden M.R. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol. Dis. 2007, 26:189-200.
63. Huang C.C., Faber P.W., Persichetti F., Mittal V., Vonsattel J.P., MacDonald M.E., Gusella J.F. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat. Cell Mol. Genet. 1998, 24:217-233.
64. Perez M.K., Paulson H.L., Pendse S.J., Saionz, Bonini N.M., Pittman R.N. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J. Cell Biol. 1998, 143:1457-1470.
65. Shimohata T., Nakajima T., Yamada M., Uchida C., Onodera O., Naruse S., Kimura T., Koide R., Nozaki K., Sano Y., Ishiguro H., Sakoe K., Ooshima T., Sato A., Ikeuchi T., Oyake M., Sato T., Aoyagi Y., Hozumi I., Nagatsu T., Takiyama Y., Nishizawa M., Goto J., Kanazawa I., Davidson I., Tanese N., Takahashi H., Tsuji S. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat. Genet. 2000, 26:29-36.
66. Sayer J.A., Manczak M., Akileswaran L., Reddy P.H., Coghlan V.M. Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin: implications for nuclear toxicity in Huntington's disease pathogenesis. Neuromolecular Med. 2005, 7:297-310.
67. Borrell-Pagès M., Zala D., Humbert S., Saudou F. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell. Mol. Life Sci. 2006, 63:2642-2660.
68. Rigamonti D., Bauer J.H., De-Fraja C., Conti L., Sipione S., Sciorati C., Clementi E., Hackam A., Hayden M.R., Li Y., Cooper, Ross C.A., Govoni S., Vincenz C., Cattaneo E. J. Neurosci. 2000, 20:3705-3713.
69. Jana N.R., Zemskov E.A., Wang G.H., Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 2001, 10:1049-1059.
70. Hermel E., Gafni J., Propp S.S., Leavitt B.R., Wellington C.L., Young J.E., Hackam A.S., Logvinova A.V., Peel A.L., Chen S.F., Hook V., Singaraja R., Krajewski S., Goldsmith P.C., Ellerby H.M., Hayden M.R., Bredesen D.E., Ellerby L.M. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ. 2004, 11:424-438.
71. Zhang Y., Engelman J., Friedlander R.M. Allele-specific silencing of mutant Huntington's disease gene. J. Neurochem. 2009, 108:82-90.
72. Majumder P., Raychaudhuri S., Chattopadhyay B., Bhattacharyya N.P. Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range. Cell. Mol. Neurobiol. 2007, 27:1127-1145.
73. Warby S.C., Doty C.N., Graham R.K., Carroll J.B., Yang Y.Z., Singaraja R.R., Overall C.M., Hayden M.R. Hum. Mol. Genet. 2008, 17:2390-2404.
74. Sun Y., Savanenin A., Reddy P.H., Liu Y.F. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-d-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 2001, 276:24713-24718.
75. Laforet G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., Cadigan B.A., Warzecki L., Tagle D.A., Reddy P.H., Cepeda C., Calvert C.R., Jokel E.S., Klapstein G.J., Ariano M.A., Levine M.S., DiFiglia M., Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J. Neurosci. 2001, 21:9112-9123.
76. Centonze D., Gubellini P., Picconi B., Saulle E., Tolu M., Bonsi P., Giacomini P., Calabresi P. An abnormal striatal synaptic plasticity may account for the selective neuronal vulnerability in Huntington's disease. Neurol. Sci. 2001, 22:61-62.
77. Lee W.T., Chang C. Magnetic resonance imaging and spectroscopy in assessing 3-nitropropionic acid-induced brain lesions: an animal model of Huntington's disease. Prog. Neurobiol. 2004, 72:87-110.
78. Fernandes H.B., Baimbridge K.G., Church J., Hayden M.R., Raymond L.A. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA induced apoptosis in YAC128 model of Huntington's disease. J. Neurosci. 2007, 27:13614-13623.
79. 2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol. Cell. Biochem. 2005, 269:143-152.
80. 2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. J. Neurosci. 2006, 26:11174-11186.
81. Milakovic T., Quintanilla R.A., Johnson G.V. Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J. Biol. Chem. 2006, 281:34785-34795.
82. Rockabrand E., Slepko N., Pantalone A., Nukala V.N., Kazantsev A., Marsh J.L., Sullivan P.G., Steffan J.S., Sensi S.L., Thompson L.M. The first 17 amino acids of huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum. Mol. Genet. 2007, 16:61-77.
83. 2+ in transgenic Huntington disease rats. J. Biol. Chem. 2008, 283:30715-30724.
84. Lim D., Fedrizzi L., Tartari M., Zuccato C., Cattaneo E., Brini M., Carafoli E. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J. Biol. Chem. 2008, 283:5780-5789.
85. 2+ buffering differences of intact neurons and astrocytes from cortex and striatum. J. Biol. Chem. 2009, 284:5010-5020.
86. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 1997, 41:646-653.
87. Tabrizin S.J., Cleeter M.W., Xuereb J., Taanman J.W., Cooper J.M., Schapira A.H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 1999, 45:25-32.
88. Trushina E., Dyer R.B., Badger J.D., Ure D., Eide L., Tran D.D., Vrieze B.T., Legendre-Guillemin V., McPherson P.S., Mandavilli B.S., Van Houten B., Zeitlin S., McNiven M., Aebersold R., Hayden M., Parisi J.E., Seeberg E., Dragatsis I., DoylE K., Bender A., Chacko C., McMurray C.T. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell. Biol. 2004, 24:8195-8209.
89. Chang D.T., Rintoul G.L., Pandipati S., Reynolds I.J. Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol. Dis. 2006, 22:388-400.
90. Kirkwood S.C., Su J.L., Conneally P., Foroud T. Progression of symptoms in the early and middle stages of Huntington disease. Arch. Neurol. 2001, 58:273-278.
91. Mahant N., McCusker E.A., Byth K., Graham S. Huntington's disease: clinical correlates of disability and progression. Neurology 2003, 61:1085-1092. Huntington Study Group.
92. Phan J., Hickey M.A., Zhang P., Chesselet M.F., Reue K. Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum. Mol. Genet. 2009, 18:1006-1016.
93. Aziz N.A., van der Burg J.M., Landwehrmeyer G.B., Brundin P., Stijnen T., Roos R.A. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 2008, 71:1506-1513. EHDI Study Group.
94. Bamford K.A., Caine E.D., Kido D.K., Plassche W.M., Shoulson I. Clinical-pathologic correlation in Huntington's disease: a neuropsychological and computed tomography study. Neurology 1989, 39:796-801.
95. Aylward E.H., Brandt J., Codori A.M., Mangus R.S., Barta P.E., Harris G.J. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994, 44:823-828.
96. Jernigan T.L., Salmon D.P., Butters N., Hesselink J.R. Cerebral structure on MRI, part II: specific changes in Alzheimer's and Huntington's diseases. Biol. Psychiatry 1991, 29:68-81.
97. Harris G.J., Aylward E.H., Peyser C.E., Pearlson G.D., Brandt J., Roberts-Twillie J.V., Barta P.E., Folstein S.E. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. Arch. Neurol. 1996, 53:316-324.
98. Aylward E.H., Li Q., Stine O.C., Ranen N., Sherr M., Barta P.E., Bylsma F.M., Pearlson G.D., Ross C.A. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997, 48:394-399.
99. Kuhl D.E., Phelps M.E., Markham C.H., Metter E.J., Riege W.H., Winter J.C. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann. Neurol. 1982, 12:425-434.
100. Young A.B., Penney J.B., Starosta-Rubinstein S., Markel D.S., Berent S., Giordani B., Ehrenkaufer R., Jewett D., Hichwa R. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann. Neurol. 1986, 20:296-303.
101. Hayden M.R., Martin W.R., Stoessl A.J., Clark C., Hollenberg S., Adam M.J., Ammann W., Harrop R., Rogers J., Ruth T. Positron emission tomography in the early diagnosis of Huntington's disease. Neurology 1986, 36:888-894.
102. Kuwert T., Lange H.W., Langen K.J., Herzog H., Aulich A., Feinendegen L.E. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 1990, 113:1405-1423.
103. Powers W.J., Videen T.O., Markham J., McGee-Minnich L., Antenor-Dorsey J.V., Hershey T., Perlmutter J.S. Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:2945-2949.
104. +-linked state 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease. J. Neurochem. 2008, 104:420-434.
105. Seong I.S., Ivanova E., Lee J.M., Choo Y.S., Fossale E., Anderson M., Gusella J.F., Laramie J.M., Myers R.H., Lesort M., MacDonald M.E. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet. 2005, 14:2871-2880.
106. Chan D.C. Mitochondrial fusion and fission in mammals. Annu. Rev. Cell Dev. Biol. 2006, 22:79-99.
107. Reddy P.H. Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. Antioxid. Redox Signal. 2007, 9:1647-1658.
108. Knott A.B., Bossy-Wetzel E. Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration. Ann. N. Y. Acad. Sci. 2008, 1147:283-292.
109. Reddy P.H., Mao P., Manczak M. Mitochondrial structural and functional dynamics in Huntington's disease. Brain Res. Rev. 2009, 61:33-48.
110. Reddy P.H., Reddy T.P., Manczak M., Calkins M.J., Shirendeb U., Mao P. Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Res. Rev. 2011, 67:103-118.
111. Wang X., Su B., Siedlak S.L., Moreira P.I., Fujioka H., Wang Y., Casadesus G., Zhu X. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19318-19323.
112. Wang X., Su B., Lee H.G., Li X., Perry G., Smith M.A., Zhu X. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J. Neurosci. 2009, 29:9090-9103.
113. Manczak M., Calkins M.J., Reddy P.H. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum. Mol. Genet. 2011, 20:2495-2509.
114. Calkins M.J., Manczak M., Mao P., Shirendeb U., Reddy P.H. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum. Mol. Genet. 2011, 20:4515-4529.
115. Wang X., Su B., Liu W., He X., Gao Y., Castellani R.J., Perry G., Smith M.A., Zhu X. DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease. Aging Cell 2011, 10:807-823.
116. Reddy P.H., Mani G., Park B.S., Jacques J., Murdoch G., Whetsell W., Kaye J., Manczak M. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J. Alzheimers Dis. 2005, 7:103-117.
117. Du H., Guo L., Yan S., Sosunov A.A., McKhann G.M., Yan S.S. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:18670-18675.
118. Bate C., Gentleman S., Williams A. α-Synuclein induced synapse damage is enhanced by amyloid-β1-42. Mol. Neurodegener. 2010, 5:55.
119. Nakamura T., Lipton S.A. Redox regulation of mitochondrial fission, protein misfolding, synaptic damage, and neuronal cell death: potential implications for Alzheimer's and Parkinson's diseases. Apoptosis 2010, 1354-1363.
120. Cookson M.R., van der Brug M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp. Neurol. 2008, 209:5-11.
121. Testa C.M., Sherer T.B., Greenamyre J.T. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res. Mol. Brain Res. 2005, 134:109-118.
122. Stephens B., Mueller A.J., Shering A.F., Hood S.H., Taggart P., Arbuthnott G.W., Bell J.E., Kilford L., Kingsbury A.E., Daniel S.E., Ingham C.A. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 2005, 132:741-754.
123. Rozas J.L., Gómez-Sánchez L., Tomás-Zapico C., Lucas J.J., Fernández-Chacón R. Presynaptic dysfunction in Huntington's disease. Biochem. Soc. Trans. 2010, 38:488-492.
124. Pérez-De La Cruz V., Elinos-Calderón D., Robledo-Arratia Y., Medina-Campos O.N., Pedraza-Chaverrí J., Ali S.F., Santamaría A. Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease. Behav. Brain Res. 2009, 199:210-217.
125. Richards P., Didszun C., Campesan S., Simpson A., Horley B., Young K.W., Glynn P., Cain K., Kyriacou C.P., Giorgini F., Nicotera P. Dendritic spine loss and neurodegeneration is rescued by Rab11 in models of Huntington's disease. Cell Death Differ. Feb 2011, 18(2):191-200.
126. Tebano M.T., Martire A., Chiodi V., Ferrante A., Popoli P. Role of adenosine A(2A) receptors in modulating synaptic functions and brain levels of BDNF: a possible key mechanism in the pathophysiology of Huntington's disease. ScientificWorldJournal 2010, 10:1768-1782.
127. André V.M., Cepeda C., Fisher Y.E., Huynh M., Bardakjian N., Singh S., Yang X.W., Levine M.S. Differential electrophysiological changes in striatal output neurons in Huntington's disease. J. Neurosci. 2011, 31:1170-11782.
128. Boudreau R.L., Monteys A.M., Davidson B.L. Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 2008, 14:1834-1844.
129. Boudreau R.L., McBride J.L., Martins I., Shen S., Xing Y., Carter B.J., Davidson B.L. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol. Ther. 2009, 17:1053-1063.
130. McBride J.L., Boudreau R.L., Harper S.Q., Staber P.D., Monteys A.M., Martins I., Gilmore B.L., Burstein H., Peluso R.W., Polisky B., Carter B.J., Davidson B.L. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:5868-5873.
131. Boudreau R.L., Martins I., Davidson B.L. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol. Ther. 2009, 17:169-175.
132. Pfister E.L., Kennington L., Straubhaar J., Wagh S., Liu W., DiFiglia M., Landwehrmeyer B., Vonsattel J.P., Zamore P.D., Aronin N. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol. 2009, 19:774-778.
133. Liu W., Kennington L.A., Rosas H.D., Hersch S., Cha J.H., Zamore P.D., Aronin N. Linking SNPs to CAG repeat length in Huntington's disease patients. Nat. Methods 2008, 5:951-953.
134. DiFiglia M., Sena-Esteves M., Chase K., Sapp E., Pfister E., Sass M., Yoder J., Reeves P., Pandey R.K., Rajeev K.G., Manoharan M., Sah D.W., Zamore P.D., Aronin N. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17204-17209.
135. Schwarz D.S., Ding H., Kennington L., Moore J.T., Schelter J., Burchard J., Linsley P.S., Aronin N., Xu Z., Zamore P.D. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet. 2006, 2:e140.
136. Aronin N. Target selectivity in mRNA silencing. Gene Ther. 2006, 13:509-516.
137. Sah D.W., Aronin N. Oligonucleotide therapeutic approaches for Huntington disease. J. Clin. Invest. 2011, 121:500-507.
138. Southwell A.L., Patterson P.H. Gene therapy in mouse models of Huntington disease. Neuroscientist 2011, 17:153-162.
139. Boudreau R.L., Rodríguez-Lebrón E., Davidson B.L. RNAi medicine for the brain: progresses and challenges. Hum. Mol. Genet. 2011, 20:R21-R27.
140. Harper S.Q., Staber P.D., He X., Eliason S.L., Martins I.H., Mao Q., Yang L., Kotin R.M., Paulson H.L., Davidson B.L. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5820-5825.
141. Cui L., Jeong H., Borovecki F., Parkhurst C.N., Tanese N., Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
142. Weydt P., Pineda V.V., Torrence A.E., Libby R.T., Satterfield T.F., Lazarowski E.R., Gilbert M.L., Morton G.J., Bammler T.K., Strand A.D., Cui L., Beyer R.P., Easley C.N., Smith A.C., Krainc D., Luquet S., Sweet I.R., Schwartz M.W., La Spada A.R. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 2006, 4:349-362.
143. St-Pierre J., Drori S., Uldry M., Silvaggi J.M., Rhee J., Jäger S., Handschin C., Zheng K., Lin J., Yang W., Simon D.K., Bachoo R., Spiegelman B.M. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006, 127:397-408.
144. Sarkar S., Ravikumar B., Floto R.A., Rubinsztein D.C. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ. 2009, 16:46-56.
145. Ravikumar B., Rubinsztein D.C. Role of autophagy in the clearance of mutant huntingtin: a step towards therapy?. Mol. Aspects Med. 2006, 27:520-527.
146. Williams A., Jahreiss L., Sarkar S., Saiki S., Menzies F.M., Ravikumar B., Rubinsztein D.C. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr. Top. Dev. Biol. 2006, 76:89-101.
147. Menzies F.M., Ravikumar B., Rubinsztein D.C. Protective roles for induction of autophagy in multiple proteinopathies. Autophagy 2006, 2:224-225.
148. Berger Z., Ravikumar B., Menzies F.M., Oroz L.G., Underwood B.R., Pangalos M.N., Schmitt I., Wullner U., Evert B.O., O'Kane C.J., Rubinsztein D.C. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 2006, 15:433-442.
149. Ravikumar B., Duden R., Rubinsztein D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 2002, 11:1107-1117.
150. Ravikumar B., Stewart A., Kita H., Kato K., Duden R., Rubinsztein D.C. Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophagy. Hum. Mol. Genet. 2003, 12:985-994.
151. Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., Scaravilli F., Easton D.F., Duden R., O'Kane C.J., Rubinsztein D.C. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004, 36:585-595.
152. Ravikumar B., Berger Z., Vacher C., O'Kane C.J., Rubinsztein D.C. Rapamycin pre-treatment protects against apoptosis. Hum. Mol. Genet. 2006, 15:1209-1216.
153. Andreassen Q.A., Dedeoglu A., Ferrante R.J., Jenkins B.G., Ferrante K.L., Thomas M., Friedlich A., Browne S.E., Schilling G., Borchelt D.R., Hersch S.M., Ross C.A., Beal M.F. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 2001, 8:479-491.
154. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 2000, 20:4389-4397.
155. Schilling G., Coonfield M.L., Ross C.A., Borchelt D.R. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett. 2001, 315:149-153.
156. Parker J.A., Arango M., Abderrahmane S., Lambert E., Tourette C., Catoire H., Néri C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet. 2005, 37:349-350.
157. Doody R.S., Gavrilova S.I., Sano M., Thomas R.G., Aisen P.S., Bachurin S.O., Seely L., Hung D., Dimebon investigators Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008, 372:207-215.
158. Bezprozvanny I. The rise and fall of Dimebon. Drug News Perspect. 2010, 23:518-523.
159. Kieburtz K., McDermott M.P., Voss T.S., Corey-Bloom J., Deuel L.M., Dorsey E.R., Factor S., Geschwind M.D., Hodgeman K., Kayson E., Noonberg S., Pourfar M., Rabinowitz K., Ravina B., Sanchez-Ramos J., Seely L., Walker F., Feigin A. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch. Neurol. 2010, 67:154-160. Huntington Disease Study Group DIMOND Investigators.